


FIG 1/7



In vitro release rate data from reservoirs prepared according to Example 1 and tested according to example 2. Dual release is combined release from reservoir 1 and 2.

- Blue (hash key): Dual drug release from reservoirs 1 and 2
- Red (square): Drug release from reservoir 1
- Green (triangle): Drug release from reservoir 2

FIG 2/7




FIG 3/7


Groups	BB (mean ± SD)	B (mean ± SD)	S (mean ± SD)
LNG 2 µg/d (N = 6)	3.83 ± 3.49	3.17 ± 3.60	3.33 ± 2.42
LNG 5 µg/d (N = 5)	0.80 ± 1.10	0.00 ± 0.00	1.40 ± 0.89
Difference (%)	- 79 %	- 100 %	- 58 %

Table 1: Mean bleeding days for comparison of 2 and 5 µg/d LNG releasing IUS's

Groups	BB (mean ± SD)	B (mean ± SD)	S (mean ± SD)
LNG 2 µg/d (N = 6)	4.00 ± 3.63	3.00 ± 3.69	3.33 ± 2.42
NP 2 µg/d (N = 6)	0.67 ± 0.82	1.50 ± 2.07	4.00 ± 3.58
Difference (%)	- 83 %	- 50 %	+ 20 %


Table 2: Mean bleeding days for comparison of 2 µg/d LNG releasing IUS group with 2 µg/d NP releasing IUS group

Fig. 4/7




5 Local progestin administration induces dose-dependent weight gain in the IUS-carrying right uterine horn (R). The left uterine horn (L) does not carry an IUS and does not show any weight gain.

FIG. 5/7



5 No decrease in LH levels occurs with compound (A) up to a dosage of 3.5 µg.
No decrease in LH levels occurs with compound (B) up to a dose range of 45 µg.

FIG. 6/7



Compound (A) exhibits a distinct increase in gene expression in the dose range from 1 µg/day upwards.
5 Levonorgestrel exhibits a distinct increase in gene expression in the dose range from 8 µg/day upwards.

FIG. 7/7



- 1 T-frame
- 2 Reservoir 2 (slow release reservoir)
- 3 Reservoir 1 (fast release reservoir)
- 4 Separation membrane
- 5a/b Locking means (optional) to hold the drug containing reservoir